Agueweed, American Scullcap, Arberry, Arctostaphylos uva-ursi, Awa, Baldarian, Bear Grape, Bearberry, Bee Bread, Blue Pimpernel, Boneset, Borage, Borago officinalis, Bugloss, Chaparral, Common Borage, Common Bugloss, Common Scullcap, Coralillo, Creosote bush, Crosswort, Eupatorium, Eupatorium perfoliatum, Feverwort, Garden Heliotrope, Gravelroot, Greaswood, Hediondilla, Helmet Flower, Hogberry, Hoodwort, Indian Sage, Kava, Kava-Kava, Kawa, Kew, Kinnikinnick, Larrea divaricata, Larrea glutinosa, Larrea tridentata, Mad-Dog Weed, Mealberry, Mountain Cranberry, Ox's Tongue, Pennyroyal, Piper methysticum, Quaker Bonnet, Rockberry, Sandberry, Scullcap, Scutellaria lateriflora, Skullcap, Starflower, Stinkweed, Sweating Plant, Teasel, Thoroughwort, Tonga, Uva Ursi, Valerian, Valeriana officinalis, Valeriana sambucifolia, Valeriana wallichi, Valeriane, Yagona.
Scientific Name: Comfrey
Other Names: Ass Ear, Black Root, Blackwort, Bruisewort, Common Comfrey, Consolidae Radix, Consound, Gum Plant, Healing Herb, Knitback, Knitbone, Salsify, Slippery Root, Symphytum Radix, Symphytum officinale, Wallwort
Who is this for?
Comfrey contains chemicals that make it unsafe to take by mouth. Known as pyrrolizidine alkaloids, some of these chemicals have been associated with liver damage in humans. Some study animals that were given comfrey developed liver cancer.
In 2001, the U.S. Food and Drug Administration (FDA) and the U.S. Federal Trade Commission (FTC) asked manufacturers to remove all oral comfrey products from the U.S. market. Oral forms of comfrey are also prohibited in several other countries, but they may be sold in some places if they are labeled as a dietary supplement. Warnings were also placed on the labels of topical products that contain comfrey. As recently as December 2003, the Canadian health organization, Health Canada, re-issued warnings that comfrey products may contain harmful chemicals and that comfrey should neither be taken orally nor be applied to raw skin.
Not all pyrrolizidine alkaloids are poisonous to humans, but the kinds, amounts, and proportions of pyrrolizidine alkaloids in comfrey products may vary greatly. Which type of comfrey plants were used, where they grew, what the weather conditions were, what time of year they were harvested, how they are processed, and where they were stored, all may affect the composition of commercial comfrey products. Similar products from different manufacturers and even different batches of the same product may have very different contents.
In addition, individual response to pyrrolizidine alkaloids is also quite variable. Some individuals, particularly children, senior adults, poorly nourished individuals, and those who have chronic illnesses, may have adverse results from doses of comfrey that are not toxic to other individuals. In a few documented case reports; however, young and middle-aged adults with no apparent health conditions are believed to have suffered liver damage from taking comfrey. The damage may be gradual, so comfrey poisoning may not be evident for periods up to 3 months.
Especially when high doses are used, or when low doses have been taken for long periods of time, pyrrolizidine alkaloids have been associated with causing a rare, but severe condition known as hepatic veno-occlusive disease. In this condition, the blood veins in the liver become clogged because a liver enzyme changes pyrrolizidine alkaloids into chemicals that may stick to the inside of veins and damage vein tissue. They may also damage lung tissue, potentially resulting in pulmonary hypertension, which is high blood pressure in the artery from the heart to the lungs. Some of the chemicals produced when pyrrolizidine alkaloids break down may stay in the body for years, continuing to damage blood vessels or other tissue.
However, comfrey contains several potentially beneficial substances that may be applied to the skin. Generally, it has high concentrations of allantoin, a protein that encourages new cells to grow; rosmarinic acid, which is known to be anti-inflammatory; and tannins, that help to firm skin tone. Because comfrey also contains mucilage, which swells in liquids, it forms a soft, sticky covering that stays in contact with the skin. All of these properties make comfrey useful when applied topically to soothe and treat bruises, minor skin irritation, and sprains. Comfrey may also have slight pain-relieving properties. It should be used only on unbroken skin, however not on large or open wounds. A mouth rinse made from comfrey may have some benefit in soothing sore gums and throat, but care must be taken not to swallow it. The mouth should be rinsed thoroughly with plain water after a comfrey rinse has been used.
When should I be careful taking it?
Comfrey should not be taken by mouth.
One case of damage to an unborn baby whose mother drank large amounts of comfrey tea during pregnancy has been reported, and birth defects are known to have occurred in laboratory animals born to mothers who were given comfrey during pregnancy. Comfrey may also have some muscle-tightening effects on the uterus. Therefore, taking it may have prompted miscarriages among laboratory animals. Additionally, potentially harmful chemicals from comfrey have been found in the milk of laboratory animals and livestock that ate it. No human studies verify that comfrey passes into human breast milk, but pregnant and breast-feeding women are advised to avoid taking comfrey by mouth.
After comfrey is applied to the skin, some of the chemicals in it may be absorbed into the body, but how much is absorbed cannot be determined in advance. Possibly, harmful amounts may accumulate, so pregnant women and women who are breast-feeding should also avoid applying topical comfrey.
Although no reliable reports of liver problems have been attributed to using comfrey on unbroken skin, individuals with liver problems and individuals who drink large amounts of alcohol should avoid its use on the skin.
Because children and the elderly may be affected by even small amounts of the pyrrolizidine alkaloids in comfrey, they should not use it in any form.
When it is used topically, comfrey should not be applied to large areas of skin or skin that is raw.
What side effects should I watch for?
When they are taken orally, the pyrrolizidine alkaloids in comfrey may be converted to toxic chemicals that have been shown to cause liver damage, primarily due to gradual blockage of blood vessels in the liver. In laboratory and farm animals, eating comfrey has resulted in liver cancer. Comfrey should never be taken by mouth.
Liver damage can take years to develop and it may not have obvious signs. Tell your doctor immediately if you are using comfrey and you experience:
Less Severe Side Effects
People who have used topical comfrey for long periods of time or in high amounts have reported:
Handling or coming in contact with the fuzzy leaves of the comfrey plant can cause skin irritation for some people.
What interactions should I watch for?
In laboratory studies, the drug phenobarbital may have caused comfrey to break down into toxic chemicals faster or more completely. Although no reports of an interaction between comfrey and phenobarbital have been reported in humans, one may be possible. Phenobarbital may be used to treat insomnia or to control seizures.
Several other herbal products, including borage, boneset, kava, pennyroyal oil, scullcap, uva ursi, and valerian, have been known to cause liver damage in humans. If comfrey is taken or applied at the same time as another herbal that may cause liver damage, the risk of liver damage could increase. Before using comfrey with other herbal products, check with your pharmacist to verify the ingredients.
Some interactions between herbal products and medications can be more severe than others. The best way for you to avoid harmful interactions is to tell your doctor and/or pharmacist what medications you are currently taking, including any over-the-counter products, vitamins, and herbals. For specific information on how comfrey interacts with drugs, other herbals, and foods and the severity of those interactions, please use our Drug Interactions Checker to check for possible interactions.
Should I take it?
Believed to have originated in Asia and Europe, comfrey now thrives in most temperate climates, At various times in history, it has been cultivated, but currently it most often grows wild in marshy areas or grassy meadows. A shrubby perennial plant that can reach 2 to 5 feet in height, it can be a nuisance choking out crops and ornamental plants, if it is not controlled. Comfrey has thick, fuzzy stems, long lower leaves, and purple or blue bell-shaped flowers that bloom throughout the summer months. In some parts of the world, comfrey leaves were eaten as a vegetable, the roots were dried and roasted for a coffee substitute, and animal feed was made from the whole plant. In the summer of 2001, the FDA required the manufacturers of oral dietary supplements for humans to stop including comfrey. Since then, comfrey has also been removed from commercial animal feeds.
The leaves, rhizomes, and roots of comfrey have all been used in medicine. Rhizomes are fleshy extensions of plant stems that run along or under the ground and often produce shoots and roots for new plants. Until the 1960s when their pyrrolizidine alkaloid content was discovered, oral forms of comfrey were taken to treat digestive and respiratory conditions. More effective and safer oral products are now on the market. Although oral forms of comfrey still may be available in the United States and other countries, taking comfrey by mouth is not recommended due to rare but severe side effects potentially caused by pyrrolizidine alkaloids it contains. In general, the underground parts of comfrey (roots and rhizomes) contain much more of the pyrrolizidine alkaloids than the leaves; and the small, new leaves have more than larger, older leaves. Comfrey may be added to creams, gels, salves, or ointments to treat conditions such as acne and psoriasis, as long as the skin is intact and not raw. It is also included in soaps, cosmetics, dry skin lotions, and lip balms.
Dosage and Administration
Due to the possibility that it may cause liver damage, comfrey is not recommended for oral use.
Topical preparations that include comfrey, such as diaper creams or chapped-lip ointments, usually contain between 5% and 20% of an extract made from the leaves or roots of comfrey. The pyrrolizidine alkaloids that make comfrey unsuitable for oral use are also absorbed through the skin. How much is absorbed is not known. Therefore, only small amounts of comfrey-containing products should be applied per day for a maximum of 10 days at a time. The use of topical comfrey preparations should be limited to a total of 6 weeks or less per year.
Applied to unbroken skin, comfrey can help relieve inflammation and soreness caused by soft tissue injuries like bruises and by minor skin irritation. It should not be applied to deep cuts or for long periods of time and it should not be taken orally.
When taken by mouth, comfrey has been reported to cause liver damage including liver cancer in animals and rare cases of veno-occlusive disease (obstructed blood vessels in the liver or lungs) in humans. While comfrey poisoning is extremely rare, it is also unpredictable. Comfrey should never be taken orally.
When comfrey products are applied to the skin, variable amounts of pyrrolizidine alkaloids may be absorbed into the body. Topical comfrey should be used in small amounts for a maximum of 10 days at a time for a total annual use of 6 weeks or less. Pregnant and breast-feeding women, children, the elderly, individuals with chronic illnesses, and individuals with known or suspected alcoholism or liver diseases should avoid using it.
When applied to the skin for long periods or in high amounts, comfrey may be associated with abdominal pain, loss of appetite, and tiredness.
Handling the leaves of the comfrey plant may result in irritation of the hands.
Reportedly, phenobarbital may accelerate and/or increase the formation of toxic chemicals from comfrey under laboratory conditions.
If comfrey is used at the same time as other herbals that could cause liver damage, the risk of liver damage may be increased.
Abbott PJ. Comfrey: assessing the low-dose health risk. Medical Journal of Australia. 1988;149(11-12):678-682.
American Academy of Pediatrics. Comfrey. February 25, 2004. Available at: http://www.ny2aap.org/herbs/prod06.htm. Accessed September 30, 2004.
American Cancer Society. Comfrey. 2002. Available at: http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Comfrey.asp?sitearea=ETO. Accessed September 30, 2004.
Anon. AAFCO framework for regulatory action on commercial animal feeds containing comfrey. FDA Veterinarian Newsletter. March/April 2003;28(2). Available at: http://www.fda.gov/cvm/index/fdavet/2003/Mar-Apr03.htm . Accessed August 6, 2004.
Anon: Comfrey. In: DerMarderosian A, Beutler JA, eds. Facts and Comparisons: The Review of Natural Products. St. Louis, MO, Facts and Comparisons. October 1995.
Association of American Feed Control Officials, Inc. Target ingredient announcement. AAFCO recommended enforcement event. Enforcement strategy for marketed ingredients (ESMI) working group. August 2002. Available at: www.aafco.org/comfrey.html. Accessed September 30, 2004.
Awang DV, Dawson BA, Fillion J, Girad M, Kindack D. Echimidine content of commercial comfrey (Symphytum spp.- Boraginaceae) Journal of Herbs, Spices and Medicinal Plants. 1993;2(1):21-34.
Bach N, Thung SN, Schaffner F. Comfrey herb tea-induced hepatic veno-occlusive disease. American Journal of Medicine. 1989;87(1):97-99.
Barrett S. FDA, FTC blast comfrey marketers. Consumer Health Digest. National Council Against Health Fraud and QuackWatch. July 23, 2001. Available at: http://www.ncahf.org/digest/01-30.html. Accessed September 30, 2004.
Bergner P. Symphytum: Comfrey, coltsfoot, and pyrrolizidine alkaloids. Medical Herbalism. 1989;1(1):1,3-5.
Bergner P. Symphytum: Comfrey is comfrey is comfrey: or is it? Medical Herbalism. 1994;6(1):13.
Bergner P. Symphytum: Hepatotoxicity of pyrrolizidine alkaloids. Medical Herbalism.1994;6(1):10.
Betz JM, Eppley RM, Taylor WC, Andrzejewski D. Determination of pyrrolizidine alkaloids in commercial comfrey products (Symphytum sp.). Journal of Pharmaceutical Sciences. 1994;83(5):649-653.
Brinker F. Coming clean on supplements designated the dirty dozen. Alternative Medicine Alert. August 2004. Available at: http://www.ahcpub.com/ahc_root_htm/hot/archive/2004/ama082004.html. Accessed September 30, 2004.
Brinker F. Herb Contraindications and Drug Interactions. Sandy, Oregon: Eclectic Institute, 1997.
Burch D, Cupp MJ. Comfrey. In Cupp, MJ. Ed. Toxicology and Clinical Pharmacology of Herbal Products. 2000. Totowa, NJ: Humana Press, Inc.
Consumer Reports. Dangerous supplements: still at large. Consumer Reports. May 2004.
Couet CE, Crews C, Hanley AB. Analysis, separation, and bioassay of pyrrolizidine alkaloids from comfrey (Symphytum officinale). Natural Toxins. 1996;4(4):163-167.
Culvenor CCJ. Estimated Intakes Of Pyrrolizidine Alkaloids By Humans. A Comparison With Dose Rates Causing Tumors In Rats. Journal of Toxicology and Environmental Health. 1983;11(4):625-635.
Dasgupta A. Review of abnormal laboratory test results and toxic effects due to use of herbal medicines. American Journal of Clinical Pathology. 2003;120(1):127-137.
Duke JA. Symphytum peregrinum Lebed. Handbook of Energy Crops. 1983. Unpublished. Available at: http://www.hort.purdue.edu/newcrop/duke_energy/ Symphytum_peregrinum.html. Accessed: September 30, 2004.
Foster S, Tyler VE. Tyler's Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. 3rd ed., Binghamton, NY: Haworth Herbal Press, 1993.
Fu PP, Yang YC, Xia Q, Chou MW, Cui YY, Lin G. Pyrrolizidine alkaloids - tumorigenic components in Chinese herbal medicines and dietary supplements. Journal of Food and Drug Analysis, 2002;10(4):198-211.
Furmanowa M, Guzewska J, Beldowska B. Mutagenic effects of aqueous extracts of Symphytum officinale L. and of its alkaloidal fractions. Journal Applied Toxicology. 1983;3(3):127-130.
Grieve M. Comfrey. In: A Modern Herbal. New York: Dover Publishers, 1971. Available at: http://www.botanical.com/botanical/mgmh/mgmh.html Posted 1995. Accessed September 30, 2004.
Haughton C. Symphytum officinale. Revised May 17, 2004. Available at: http://www.purplesage.org.uk/profiles/comfrey.htm. Accessed September 30, 2004.
Herbs2000. Comfrey. No date given. Available at: http://www.herbs2000.com/herbs/herbs_comfrey.htm. Accessed September 30, 2004.
Hirono I, Mori H, Haga M. Carcinogenic activity of Symphytum officinale. Journal of the National Cancer Institute. 1978;61(3):865-869.
Hoffmann DL. Comfrey. Herbal Materia Medica. No date given. Available at: http://www.healthy.net/asp/templates/article.asp?PageType=article&ID=1648. Accessed September 30, 2004.
Huxtable RJ. The harmful potential of herbal and other plant products. Drug Safety. 1990;5(Suppl 1):126-136.
Huxtable RJ, Awang DV. Pyrrolizidine poisoning. [Letter] American Journal of Medicine. 1990;89(4):547-548.
International Programme [sic] on Chemical Safety. Environmental health criteria 80. Pyrrolizidine alkaloids. World Health Organization. 1988. Available at: http://www.inchem.org/documents/ehc/ehc/ehc080.htm.. Accesses October 5, 2004.
Jellin JM, Gregory P, Batz F, Hitchens K, et al, eds. Pharmacist's Letter/Prescriber's Letter. Natural Medicines Comprehensive Database, 3rd Edition. Stockton CA: Therapeutic Research Facility, 2000.
Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. American Journal of Health System Pharmacy. 1999;56:125-138.
Koll R, Klingenburg S. Therapeutic characteristance [sic] and tolerance of topical comfrey preparations. Results of an observational study of patients. [Article in German] Fortschr Med Orig. 2002;120(1):1-9.
Lafranconi WM, Huxtable RJ. Hepatic metabolism and pulmonary toxicity of monocrotaline using isolated perfused liver and lung. Biochemistry and Pharmacology. 1984;33(15):2479-2484.
Lafranconi WM, Ohkuma S, Huxtable RJ. Biliary excretion of novel pneumotoxic metabolites of the pyrrolizidine alkaloid, monocrotaline. Toxicon. 1985;23(6):983-992.
Larrey D. Liver involvement in the course of phytotherapy. [Article in French] Presse Medicale. 1994;23(15):691-693.
Lewis CJ. FDA advises dietary supplement manufacturers to remove comfrey products from the market. [letter]. July 6, 2001. Available at: http://vm.cfsan.fda.gov/~dms/dspltr06.html Accessed February 3, 2003.
Manteiga R, Park DL, Ali SS. Risks associated with consumption of herbal teas. Review of Environmental Contaminants and Toxicology. 1997;150:1-30.
Mattocks AR. Toxic pyrrolizidine alkaloids in comfrey. Lancet. 1980;2(8204):1136-1137.
McDermott WV, Ridker PM. The Budd-Chiari syndrome and hepatic veno-occlusive disease. Recognition and treatment. Archives of Surgery. 1990;125(4):525-527.
McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Product Associations Botanical Safety Handbook. Boca Raton, FL: CRC Press; 1997.
Panter KE, James LF. Natural plant toxicants in milk: a review. Journal of Animal Sciences. 1990;68(3):892-904.
Prakash AS, Pereira TN, Reilly PE, Seawright AA. Pyrrolizidine alkaloids in human diet. Mutation Research. 1999;443(1-2):53-67.
Ridker PN, McDermott WV. Hepatotoxicity due to comfrey herb tea. [Letter] American Journal of Medicine. 1989;87(6):701.
Ridker PM, Ohkuma S, McDermott WV, Trey C, Huxtable RJ. Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology. 1985;88(4):1050-1054.
Rode D. Comfrey toxicity revisited. Trends in Pharmacological Science. 2002;23(11):497-499.
Roitman JN. Comfrey and liver damage. Lancet. 1981;1(8226):944.
Roulet M, Laurini R, Rivier L, Calame A. Hepatic veno-occlusive disease in newborn infant of a woman drinking herbal tea. Journal of Pediatrics. 1988;112(3):433-436.
Shipochliev T. Uterotonic action of extracts from a group of medicinal plants. [Article in Bulgarian] Vet Med Nauki. 1981;18(4):94-98.
Shipochliev T, Dimitrov A, Aleksandrova E. [Anti-inflammatory action of a group of plant extracts [Article in Bulgarian] Vet Med Nauki. 1981;18(6):87-94.
Sievers AF. The Herb Hunters Guide. Misc Publication No. 77. 1930. U.S. Department of Agriculture. Washington, DC.
Smith LW, Culvenor CC. Plant sources of hepatotoxic pyrrolizidine alkaloids. Journal of Natural Products. 1981;44(2):129-152.
Sommer M. Hepatic veno-occlusive disease and drinking of herbal teas. Journal of Pediatrics. 1989;115(4):659-660.
Steenkamp V, Stewart MJ, Zuckerman M. Clinical and analytical aspects of pyrrolizidine poisoning caused by South African traditional medicines. Therapeutic Drug Monitoring. 2000;22(3):302-306.
Stegelmeier BL, Edgar JA, Colegate SM, Gardner DR, Schoch TK, Coulombe RA, Molyneux RJ. Pyrrolizidine alkaloid plants, metabolism and toxicity. Journal of Natural Toxins. 1999;8(1):95-116.
Stewart MJ, Steenkamp V. Pyrrolizidine poisoning: a neglected area in human toxicology. Therapeutic Drug Monitoring. 2001;23(6):698-708.
Stickel F, Seitz HK. The efficacy and safety of comfrey. Public Health and Nutrition. 2000;3(4A):501-508.
Teynor, TM, Putnam, DH, Doll JD, Kelling KA, Oelke, D.J. Undersander DJ, Oplinger ES. Comfrey. Updated November 17, 1997. Available at: http://www.hort.purdue.edu/newcrop/afcm/comfrey.html. Accessed September 30, 2004.
Weston CF, Cooper BT, Davies JD, Levine DF. Veno-occlusive disease of the liver secondary to ingestion of comfrey. British Medical Journal (Clinical Research Edition). 1987;295(6591):183.
Wuilloud JCA, Gratz SR, Wolnik KA.. COMFREY II: Investigation of pyrrolizidine alkaloids and their N-oxides in commercial comfrey-containing products and botanical materials by LC-ESI-MS. [Poster abstract A-73] Presented at the 10th FDA Science Forum. May 18-19, 2004. Washington, D.C.
Wuilloud JCA, Gratz SR, Gamble BM, Wolnik KA. COMFREY I: Simultaneous analysis of hepatotoxic pyrrolizidine alkaloids and N-oxides in comfrey root by LC-ion trap mass spectrometry. [Poster abstract A-73] Presented at the 10th FDA Science Forum. May 18-19, 2004. Washington, D.C.
Yeong ML, Clark SP, Waring JM, Wilson RD, Wakefield SJ. The effects of comfrey derived pyrrolizidine alkaloids on rat liver. Pathology. 1991;23(1):35-38.
Yeong ML, Swinburn B, Kennedy M, Nicholson G. Hepatic veno-occlusive disease associated with comfrey ingestion. Journal of Gastroenterology and Hepatology. 1990;5(2):211-214.
Yeong ML, Wakefield SJ, Ford HC. Hepatocyte membrane injury and bleb formation following low dose comfrey toxicity in rats. International Journal of Experimental Pathology. 1993;74(2):211-217.
(Note: The above information is not intended to replace the advice of your physician, pharmacist, or other healthcare professional. It is not meant to indicate that the use of the product is safe, appropriate, or effective for you.)